Pharmadrug Inc.
PHRX.CN
Canadian Securities Exchange0.01
CAD
+0.01
- -
Pharmadrug Inc.
PHRX.CN
(Canadian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PharmaDrug Inc. is a specialty pharmaceutical company engaged in the research, development, and commercialization of controlled substances and natural medicines, including psychedelics and previously approved drugs. The company's core products and services include the development and clinical advancement of reformulated natural-based medicines targeting oncology and infectious diseases; synthetic formulations of existing drugs tailored to meet emerging drug policy reforms; and the development of cepharanthine, a patented enteric-coated formulation for treating infectious diseases and rare cancers. PharmaDrug operates through subsidiaries such as Sairiyo Therapeutics, which focuses on reformulating natural medicines for clinical trials and regulatory approval, and SecureDose Synthetics, which has recently ceased operations due to strategic shifts. Founded and headquartered in Toronto, Ontario, PharmaDrug primarily serves the biotechnology and pharmaceutical sectors with a focus on therapeutic molecules and medical products derived from natural sources. Its recent strategic initiatives include a definitive agreement to acquire up to a 40% equity interest in Canurta Inc., a biotechnology firm pioneering botanical therapeutics for inflammatory and neurodegenerative diseases, enhancing PharmaDrug’s biotechnology profile and pipeline with innovative drug candidates like CNR-401 targeting Amyotrophic Lateral Sclerosis (ALS). Additionally, PharmaDrug is advancing the clinical development of PD-001, its patented cepharanthine formulation, supported by contracts such as a $3.4 million award from the U.S. Defense Threat Reduction Agency to conduct Phase 1 clinical trials. In 2025, PharmaDrug undertook a comprehensive strategic review process led by independent directors to explore potential asset sales, restructurings, and consolidation opportunities aimed at maximizing shareholder value. This review also led to the discontinuation of SecureDose's operations, aligning the company’s focus solely on clinical and commercial development of therapeutic molecules. PharmaDrug's activities span North America with an emphasis on leveraging its proprietary clinical development platforms and strategic collaborations to enhance its pipeline and expand commercial presence in the natural and controlled substances pharmaceutical space. The company continues to pursue growth through partnerships, biotechnology investments, and innovative therapeutic drug development.